OL
TCRT icon

Owen LaRue’s Alaunos Therapeutics TCRT Stock Holding History

Owen LaRue’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-79
Closed -$836 – 94
2023
Q4 		$836 Hold
79
– – ﹤0.01% 74
2023
Q3 		$1.56K Hold
79
– – ﹤0.01% 72
2023
Q2 		$5.89K Hold
79
– – 0.01% 73
2023
Q1 		$7.76K Hold
79
– – 0.01% 72
2022
Q4 		$7.76K Buy
+79
New +$11.4K 0.01% 72

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Owen LaRue's TCRT Position: Q1 2024 in Review

Owen LaRue sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 79 shares — an estimated $836 sold.

Owen LaRue first reported a position in TCRT in Q4 2022 and held it in 5 quarters. The position peaked at $7.76K in Q1 2023. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Owen LaRue reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Owen LaRue sold 79 Alaunos Therapeutics shares in Q1 2024, an estimated $836.
  • Owen LaRue first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 5 quarters.
  • Owen LaRue's Alaunos Therapeutics position peaked at $7.76K in Q1 2023.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Owen LaRue's 13F filing for Q1 2024, filed 13 May 2024.